Ginkgolide in Ischmic Stroke patients with large Artery Atherosclerosis(GISAA):A randomized, double-blinded, multicenter, placebo-controlled study

Q. Dong

DOI: https://doi.org/10.31488/bjhd.106

2020-01-01

Abstract:Background The Global Burden of Disease 2013 study shows that although stroke incidence, prevalence, mortality, and disability-adjusted life-years rates tend to decline from 1990 to 2013, the absolute number of people who have a stroke every year, stroke survivors, related deaths, and the overall global burden of stroke are great and increasing, particularly in low-to-middle income countries [1]. In China, stroke is the second leading cause of death, and ischemic stroke is the most common stroke subtype. According to the Trial of Org 10172 in Acute Stroke Treatment (TOAST), stroke is classified into large artery atherosclerotic type, cardiogenic cerebral embolism, small artery block type, lacunar stroke, other causes and ischemic stroke of unknown cause. Tsai CF et al reported that the proportion of strokes due to Large Artery Atherosclerosis (LAA) ranged from 12% to 54%, small vessel disease 20% to 42%, cardioembolism 10% to 26%, and the combination of other specific determined and undetermined etiology subtypes 4% to 34% [2]. Of all ischemic strokes, LAA of the head and neck is responsible for approximately 15% of stroke [3]. However, LAA is the leading stroke subtype in China[4]. In many Asian countries, LAA often affects the middle cerebral artery, intracranial portion of the internal carotid artery, and vertebrobasilar artery, which is estimated to 33%-50% of stroke in Chinese stroke populations [5]. The risk of early recurrent stroke is high in those patients with LAA. It has been reported that the risk of recurrent stroke might be as Received: Novemeber 28, 2018; Accepted: December 28, 2018; Published: December 31, 2018